Can-Fite Biopharma Ltd CANF

Namodenoson treatment shows improvement in decompensated cirrhosis and enables successful bridging to liver transplantation per new publication on Can-Fite Biopharma. Positive Namodenoson data for cirrhosis advances core drug pipeline and supports major trajectory shift for Can-Fite.

Can-Fite Biopharma Ltd reported Q2 2026 financial results and clinical progress in its ongoing pivotal Phase III liver cancer study, noting longer-than-anticipated overall survival. Positive survival data from a pivotal Phase III oncology trial can materially shift company valuation and investor sentiment.

Can-Fite Biopharma Ltd reports longer-than-anticipated overall survival in its ongoing pivotal Phase III liver cancer study. Positive survival data from pivotal Phase III liver cancer trial strengthens approval prospects and commercial outlook.

Can-Fite BioPharma evaluates conducting an earlier interim analysis for its pivotal liver cancer study. Earlier interim analysis option for the liver cancer trial may shift clinical timelines and short-term investor views.

Can-Fite's Namodenoson enhances chemotherapy anti-cancer effects in pancreatic cancer. Positive Namodenoson data in pancreatic cancer strengthens Can-Fite pipeline and investor outlook.

Can-Fite Biopharma Ltd reports advanced FDA and EMA regulatory status for its Phase III drug candidates. Advanced FDA and EMA status for Phase III candidates signals potential regulatory approvals boosting company prospects.

Can-Fite Biopharma Ltd launches first clinical program for Piclidenoson in Lowe Syndrome, a rare genetic disease. New clinical program in rare disease expands pipeline and may moderately lift visibility and valuation.

Can-Fite Biopharma's positive Phase 2a pancreatic cancer study data has been accepted for presentation at the ESMO Congress 2026. Phase 2a data acceptance at major oncology congress may boost Can-Fite research visibility and near-term sentiment without altering core trajectory.

Can-Fite Biopharma secures Australian patent allowance for Namodenoson supporting development and marketing in liver and pancreatic cancer. Australian patent allowance expands Namodenoson IP protection in oncology indications.

Can-Fite Biopharma completed patient enrollment for the interim analysis in its pivotal Phase 3 psoriasis trial. Results are expected in Q4 2026 or Q1 2027. Phase 3 enrollment completion marks trial progress for psoriasis candidate but results remain years away.

Can-Fite Phase 2a pancreatic cancer trial of Namodenoson met primary safety endpoint and showed durable survival in advanced disease. Positive Phase 2a Namodenoson data strengthens Can-Fite pipeline prospects and investor sentiment for oncology development.

Can-Fite Biopharma Ltd secures Japanese patent allowance for Namodenoson anti-obesity technology. Japanese patent strengthens Namodenoson IP protection and supports potential obesity indication expansion in one market.

Can-Fite Biopharma reports positive clinical observations from its Phase 2a pancreatic cancer study and highlights Namodenoson's RAS signaling inhibition mechanism. Positive Phase 2a pancreatic cancer data plus RAS inhibition mechanism may drive significant investor interest and alter company trajectory.

Can-Fite and Vetbiolix published scientific findings that validate Piclidenoson for treating canine osteoarthritis in a multi-billion-dollar market. Publication validates Piclidenoson for canine osteoarthritis and opens a major new market opportunity for Can-Fite.

Can-Fite Biopharma advances Namodenoson into Phase 2b combination study with immunotherapy after positive Phase 2a pancreatic cancer data. Advancing Namodenoson to Phase 2b with immunotherapy post-positive Phase 2a pancreatic cancer data marks a major pipeline progression for CANF.

Can-Fite Biopharma Ltd reported positive Phase 2a data for Namodenoson in pancreatic cancer, with 35% of patients remaining on therapy including one beyond 16 months. Positive Phase 2a pancreatic cancer data with durable responses signals potential pipeline advancement and stock catalyst for biotech.

Can-Fite Biopharma's partner Vetbiolix completes enrollment in Phase 2 osteoarthritis study in dogs using Piclidenoson; topline data expected in Q3 2026. Phase 2 enrollment completion advances Piclidenoson in veterinary osteoarthritis via partner, potentially boosting pipeline sentiment but data delayed until 2026.

Can-Fite Biopharma Ltd (CANF) reported 2025 financial results and clinical progress, including positive Phase 2a data in pancreatic cancer treatment and a liver cancer patient remaining cancer-free for 9 years. Positive Phase 2a pancreatic cancer data combined with long-term liver cancer survival evidence could significantly enhance clinical prospects and drive stock momentum.

Can-Fite Biopharma Ltd receives Israeli patent allowance for Namodenoson in obesity and related conditions like fatty liver disease, expanding its anti-obesity franchise and bolstering IP protection ahead of Phase II trials. Israeli patent allowance for Namodenoson in obesity enhances IP portfolio and supports franchise expansion into a high-demand market without guaranteeing regulatory or commercial success.

CANF stock soars 20% on positive mid-stage pancreatic cancer data. Positive mid-stage pancreatic cancer trial data triggered 20% stock surge, potentially advancing key oncology pipeline toward Phase 3 and partnerships.

Can-Fite Biopharma Ltd's Namodenoson successfully met its primary endpoint in a Phase 2a clinical study for pancreatic cancer, demonstrating promising efficacy and safety. Phase 2a success in pancreatic cancer trial advances Namodenoson toward Phase 3 and significantly boosts CANF's pipeline and investor sentiment.

Can-Fite Biopharma Ltd announced the exercise of warrants for approximately $4.0 million in gross proceeds. Warrant exercise injects $4 million in cash, supporting financial runway but not transforming operations or prospects.

Can-Fite Biopharma Ltd announced a scientific breakthrough publication demonstrating Namodenoson's anti-obesity effect in preclinical models, highlighting its potential to reduce body weight and fat mass via A3AR activation. Namodenoson's demonstrated anti-obesity effects expand Can-Fite's pipeline into a high-demand market, likely enhancing investor sentiment and market performance.

Can-Fite Biopharma Ltd has received a patent allowance in Canada for its drug Namodenoson, which is being developed as a therapy for obesity. This patent could enhance the company's intellectual property portfolio and support its market position in the anti-obesity sector. The Canadian patent allowance for Namodenoson is a significant strategic move that could enhance Can-Fite's competitive positioning in the anti-obesity market.

A patient with decompensated liver cirrhosis successfully underwent liver transplantation after receiving treatment with Can-Fite Biopharma's Namodenoson. This case highlights the potential of Namodenoson as a therapeutic option for patients with severe liver conditions, showcasing its efficacy in a critical medical scenario. Successful liver transplantation following treatment with Namodenoson indicates significant therapeutic potential, likely enhancing investor sentiment and market position.

Can-Fite Biopharma Ltd has successfully completed patient enrollment for its Phase 2a clinical study of Namodenoson, a drug being tested for the treatment of pancreatic cancer. The study aims to evaluate the safety and efficacy of Namodenoson in patients with advanced stages of the disease. This milestone marks a significant step in the company's efforts to develop new therapeutic options for pancreatic cancer, which has limited treatment alternatives. Completion of patient enrollment in a Phase 2a study is a significant step that could influence future product development and investor sentiment.

Can-Fite Biopharma Ltd has been granted a patent in Brazil for a treatment aimed at sexual dysfunction. This patent is expected to enhance the company's intellectual property portfolio and may facilitate future market opportunities in Brazil, a significant market for such treatments. The Brazilian patent could significantly impact Can-Fite's market positioning and revenue potential in a key therapeutic area.

Can-Fite Biopharma Ltd announced a reverse split of its ordinary shares and a change in the American Depositary Shares (ADS) ratio. The reverse split is aimed at increasing the per-share price to meet listing requirements and enhance marketability. The new ADS ratio will be 1-for-10, meaning that every ten existing ADSs will be consolidated into one new ADS. This move is part of the company's strategy to improve its stock performance and attract more investors. The reverse split and ADS ratio change may influence market sentiment and stock performance but are not expected to fundamentally alter the company's trajectory.

Can-Fite Biopharma Ltd provided an update on its clinical and financial status, highlighting advancements in its drug development pipeline and recent financial results. The company is focused on progressing its lead drug candidates through clinical trials and is actively seeking partnerships to enhance its market position. Financially, Can-Fite reported its latest earnings, indicating a stable cash position to support ongoing operations and research initiatives. The updates on clinical progress and financial stability suggest a moderate influence on Can-Fite's future performance and market sentiment.

Can-Fite Biopharma Ltd will present updates on its advanced stage drug pipeline at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference. The presentation aims to highlight the company's progress and potential in the pharmaceutical sector, focusing on its innovative treatments and strategic developments. The presentation of advanced stage drug pipeline developments is likely to significantly impact investor sentiment and the company's future performance.